Despite similar immune cell infiltrate signatures between ICB combined with EGFR inhibition and EGFR inhibition alone, growth data suggest an improved antitumour response in aPD-1 + erlotinib mice, resulting in a faster reduction in tumour size and slower tumour progression until the end of the experiments (Figure 5A). This evidence concerns the gene EGFR and neoplasm.